ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO0729

Reversal of CD4:CD8 Ratio May Predict Infection Risk in Patients with ANCA-Associated Vasculitis

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

  • Thanikachalam, Prakash, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, England, United Kingdom
  • Joshi, Anivart, King's College London, London, England, United Kingdom
  • Morris, Adam, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, England, United Kingdom
  • Floyd, Lauren, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, England, United Kingdom
  • Ponnusamy, Arvind, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, England, United Kingdom
  • Rowbottom, Anthony Walter, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, England, United Kingdom
  • Elsayed, Mohamed Elsayed, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, England, United Kingdom
  • Dhaygude, Ajay Prabhakar, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, England, United Kingdom
Background

Infection is a leading cause of morbi-mortality in AAV. Immune frailty increases this risk but is hard to measure. T lymphocytes are key mediators of cellular immunity. The CD4:CD8 ratio is a useful marker of immune function. Age, sex, ethnicity and genetics, influence the CD4:CD8 ratio and an inverted ratio is associated with immune malfunction and immunosenescence. Role of ratio reversal in AAV remains unclear. We aim to examine the CD4:CD8 ratio and outcomes in AAV patients.

Methods

Retrospective study was conducted in a single centre between 2012 and 2022. All the patients seen in vasculitis clinic with 2 years follow up and CD4:CD8 ratio taken prior to exposure to maximum of 1g of cyclophosphamide were included. Regression analysis was used to establish relationships between CD4:CD8 ratio and outcomes.

Results

43 patients with AAV were included, 56% (n=24) were male and the mean age was 63.0 years. A decrease in CD4:CD8 ratio was associated with an increased risk of infections requiring hospitalization. Logarithmic CD4:CD8 ratio showed significantly high risk of infection (p = 0.0432, estimated coefficient = -0.6838). This was independent from age and Charleson Comorbidity Index (p = 0.5972 and p = 0.2111 respectively).

Conclusion

This study showed decreased CD4:CD8 ratio to be a significant independent risk factor associated with increased risk of infections. This requires confirming in a large cohort and may prove more important that physical frailty in terms of risk stratification in the management of AAV.
Limitations: Small sample size.

Digital Object Identifier (DOI)